AUTHORS
Amog P Urs, PhD, Chinmayee Goda, PhD2, Yaphet Bustos, BS3, Wenjun Li4, Adrienne M. Dorrance, PhD5, Mahesh Chandrasekharan, PhD, MSc6, Ramiro Garzon, MD7
AFFILIATIONS
1 Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, United States
2 Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, United States
3 Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, United States
4 Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, United States
5 Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, United States
6 Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, United States
7 Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, United States
ABSTRACT
Background: Philadelphia chromosome-positive (BCR::ABL1-positive) B-cell acute lymphoblastic leukemia (Ph+ B-ALL) is an aggressive disease driven by constitutively active BCR::ABL1 tyrosine kinase, which fuels proliferation while generating replication stress and genomic instability. We previously identified circPCMTD1, a protein-coding circular RNA that produces the cPCMTD1-127aa peptide. Although circPCMTD1 is expressed across normal and malignant hematopoietic cells, Ph+ cells are selectively sensitive to its depletion. In blast-phase chronic myeloid leukemia, cPCMTD1-127aa interacts with BCR::ABL1 and binds directly to the BLM–TOP3A–RMI1 (BTR) complex, stabilizing complex formation and promoting tolerance of replication-associated DNA damage. CircPCMTD1 depletion disrupts BTR complex assembly, increases DNA damage, induces G2/M arrest, potentiates dasatinib efficacy, and retains antileukemic activity in TKI-resistant cells (Papaioannou et al., Blood 2026). Here, we investigate the functional relevance of circPCMTD1 in Ph+ B-ALL.
Methods: We used a locked nucleic acid (LNA)-modified, RNase H-recruiting gapmer (250 nM) targeting the circPCMTD1 back-splice junction. Quantitative real-time PCR confirmed selective circPCMTD1 knockdown in the p190 BCR::ABL1-positive Z-181 B-ALL cell line, with linear PCMTD1 unaffected. All cell-line experiments were performed in ≥3 biological replicates.
Results: CircPCMTD1 knockdown reduced proliferation and induced G2/M arrest relative to control. At 72 hours, the mean S-phase fraction fell from 55% to 30%, while G2/M fraction rose from 36% to 51%. At 96 hours, ATP-based luminescence viability assays showed a mean relative proliferation reduction to 67% of control, and Annexin V/DAPI staining showed a 30% reduction in the viable fraction, with a corresponding increase in apoptosis. In primary B-ALL samples, anti-circPCMTD1 gapmer treatment achieved ~65–85% knockdown in Ph+ blasts (n=3) and markedly increased γH2AX at 48 hours. Ph-negative B-ALL samples (n=3) showed minimal γH2AX induction, indicating a BCR::ABL1-associated vulnerability rather than a difference in circPCMTD1 expression. CircPCMTD1 depletion reduced primary colony formation in every Ph+ donor and decreased secondary replating by ~50–68%. Cord blood-derived CD34+ cells retained colony-forming capacity despite comparable (75%) knockdown, indicating a therapeutic window. In a primary Ph+ B-ALL patient-derived xenograft (PDX) model, systemic anti-circPCMTD1 gapmer treatment initiated at 5–10% human engraftment extended median survival from ~11 to 15 weeks (n=15/group; log-rank P<0.0001).
Discussion: BCR::ABL1-positive leukemias depend on genome-maintenance pathways for survival, and our data implicates circPCMTD1/cPCMTD1-127aa as a contributor to this dependency in Ph+ disease. We are therefore pursuing a mechanism-based strategy to disrupt genome maintenance in Ph+ B-ALL by targeting circPCMTD1, alone or in combination. We previously showed that selective inhibition of histone deacetylases 1 and 2 (HDAC1,2) disrupts the MRE11–RAD51–DNA ligase 1 repair axis and reduces leukemia burden in PDX models of refractory, TKI-resistant Ph+ B-ALL (Tharkar-Promod et al., Leukemia 2018). Preliminary data show that combining circPCMTD1 depletion with a selective HDAC1,2 inhibitor suppresses proliferation, cell-cycle progression, and clonogenic growth more effectively than either agent alone. Ongoing work includes dose-matrix synergy analysis, testing in TKI-resistant models, in vivo validation of the combination, and development of orthogonal therapeutic approaches targeting cPCMTD1-127aa.
Conclusion: We identify circPCMTD1 as a key regulator of genome stability, cell-cycle progression, and clonogenic capacity in Ph+ B-ALL. Despite its broad expression, circPCMTD1 constitutes a BCR::ABL1-associated functional dependency shared across myeloid and lymphoid leukemias. These findings establish circPCMTD1 and cPCMTD1-127aa as candidate therapeutic targets and support combining circPCMTD1-directed therapy with epigenetic/DNA repair modulators to disrupt genome-maintenance networks essential for BCR::ABL1-positive leukemic cell survival. Future studies will determine whether these mechanism-based combinations eradicate therapy-persistent leukemia-initiating cells and prevent relapse.
DISCLOSURES
Amog P Urs, PhD: No relevant conflicts of interest to declare.